Ref. No: Date: Subject: 0331 10/10/23

Melanoma & RCC

REQUEST

I have a Freedom of Information request regarding the treatment of renal cell carcinoma and melanoma. Could you please answer the following questions:

- 1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
 - Avelumab + Axitinib
 - Axinitib
 - Cabozantinib
 - Everolimus
 - Lenvantinib + Everolimus
 - Nivolumab monotherapy
 - Nivolumab + Cabozantinib
 - Nivolumab + Ipilimumab
 - Pazopanib
 - Pembrolizumab monotherapy

- Pembrolizumab + Axitinib
- Pembrolizumab + Lenvatinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anticancer therapy
- Palliative care only
- 2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
 - Cobimetinib
 - Dabrafenib
 - Dabrafenib AND Trametinib
 - Dacarbazine
 - Denosumab
 - Encorafenib AND Binimetinib
 - Ipilimumab
 - Ipilimumab AND Nivolumab

- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anticancer therapy
- Palliative care only

3. Does you Trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

We do not keep indications on the Pharmacy system to know this information. However- Renal cell carcinoma and melanoma are both solid tumours which would be initiated and treated under Clatterbridge consultants. (STHK)

This condition is not treated at S&O

2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

We do not keep indications on the Pharmacy system to know this information. However- Renal cell carcinoma and melanoma are both solid tumours which would be initiated and treated under Clatterbridge consultants. (STHK)

This condition is not treated at S&O

3. Does you Trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

We do not have any active clinical trials for the treatment of renal cell carcinoma.